Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8)

Journal of Pharmaceutical Sciences

Volumn 102, Issue 9, 2013, Pages 3451-3457

  Yee, Sook Wah ^a   Nguyen, Anh Nguyet ^a   Brown, Chaline ^a   Savic, Radojka M ^a   Zhang, Youcai ^a   Castro, Richard A ^a   Cropp, Cheryl D ^a   Choi, Ji Ha ^a   Singh, Diment ^a   Tahara, Harunobu ^a   Stocker, Sophie L ^a   Huang, Yong ^a   Brett, Claire M ^a   Giacomini, Kathleen M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cefotaxime; OAT3; Organic anion transporter; Pharmacogenomic; Pharmacokinetics; Polymorphisms; Renal clearance; Tubular secretion

Indexed keywords

CEFOTAXIME; CREATININE; ORGANIC ANION TRANSPORTER 3;

ADULT; AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG TRANSPORT; FEMALE; GENE FREQUENCY; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; KIDNEY CLEARANCE; KIDNEY TUBULE EXCRETION; MICHAELIS CONSTANT; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

CEFOTAXIME; OAT3; ORGANIC ANION TRANSPORTER; PHARMACOGENOMIC; PHARMACOKINETICS; POLYMORPHISMS; RENAL CLEARANCE; TUBULAR SECRETION;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CEFOTAXIME; FEMALE; GENE FREQUENCY; HEK293 CELLS; HUMANS; KIDNEY; MALE; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 84881614134     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23581     Document Type: Article

References (39)

1. Sato M, Mamada H, Anzai N, Shirasaka Y, Nakanishi T, Tamai I. 2010. Renal secretion of uric acid by organic anion transporter 2 (OAT2/SLC22A7) in human. Biol Pharm Bull 33:498-503.
2. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H. 2001. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59:1277-1286.
3. Nagle MA, Truong DM, Dnyanmote A Ahn SY, Eraly SA, Wu W, Nigam SK. 2011. Analysis of three-dimensional systems for developing and mature kidneys clarifies the role of OAT1 and OAT3 in antiviral handling. J Biol Chem 286:243-251.
4. Morrissey, KM, Stocker, SL, Wittwer, MB, Xu L, Giacomini KM. 2012. Renal transporters in drug development. Annu Rev Pharmacol Toxicol 53:503-529.
5. Vanwert AL, Srimaroeng C, Sweet DH. 2008. Organic anion transporter 3 (Oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin. Mol Pharmacol 74:122-131.
6. VanWert AL, Sweet DH. 2008. Impaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: A gender specific impact of reduced folates. Pharm Res 25:453-462.
7. Vanwert AL, Bailey RM, Sweet DH. 2007. Organic anion transporter 3 (Oat3/Slc22a8) knockout mice exhibit altered clearance and distribution of penicillin G. Am J Physiol Renal Physiol 293:F1332-F1341.
8. Jaehde U, Sorgel F, Reiter A, Sigl G, Naber KG, Schunack W. 1995. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clin Pharmacol Ther 58:532-541.
9. Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CP. 1995. Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. Br J Clin Pharmacol 39:692-695.
10. Erdman AR, Mangravite LM, Urban TJ, Lagpacan LL, Castro RA, de la Cruz M, Chan W, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, Carlson EJ, Ferrin TE, Brett CM, Burchard EG, Giacomini KM. 2006. The human organic anion transporter 3 (OAT3; SLC22A8): Genetic variation and functional genomics. Am J Physiol Renal Physiol 290:F905-912.
11. Xu G, Bhatnagar V, Wen G, Hamilton BA, Eraly SA, Nigam SK. 2005. Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)]. Kidney Int 68:1491-1499.
12. Ogasawara K, Terada T, Motohashi H, Asaka J, Aoki M, Katsura T, Kamba T, Ogawa O, Inui K. 2008. Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney. J Hum Genet 53:607-614.
13. Bhatnagar V, Xu G, Hamilton BA, Truong DM, Eraly SA, Wu W, Nigam SK. 2006. Analyses of 5' regulatory region polymorphisms in human SLC22A6 (OAT1) and SLC22A8 (OAT3). J Hum Genet 51:575-580.
14. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K, Sugiyama Y. 2003. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554-565.
15. Vormfelde SV, Schirmer M, Hagos Y, Toliat MR, Engelhardt S, Meineke I, Burckhardt G, Nurnberg P, Brockmoller J. 2006. Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. Br J Clin Pharmacol 62:323-335.
16. Han YF, Fan XH, Wang XJ, Sun K, Xue H, Li WJ, Wang YB, Chen JZ, Zhen YS, Zhang WL, Zhou X, Hui R. 2011. Association of intergenic polymorphism of organic anion transporter 1 and 3 genes with hypertension and blood pressure response to hydrochlorothiazide. Am J Hypertens 24:340-346.
17. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA. 2012. An integrated map of genetic variation from 1, 092 human genomes. Nature 491:56-65.
18. Prasad K, Kumar A, Gupta PK, Singhal T. 2007. Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis. Cochrane Database Syst Rev CD001832.
19. Ings RM, Fillastre JP, Godin M, Leroy A, Humbert G. 1982. The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function. Rev Infect Dis (4 Suppl):S379-S391.
20. Esmieu F, Guibert J, Rosenkilde HC, Ho I, Le Go A. 1980. Pharmacokinetics of cefotaxime in normal human volunteers. J Antimicrob Chemother 6(Suppl A):83-92.
21. Benet LZ, Broccatelli F, Oprea TI. 2011. BDDCS applied to over 900 drugs. AAPS J 13:519-547.
22. Ings RM, Reeves DS, White LO, Bax RP, Bywater MJ, Holt HA. 1985. The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. J Pharmacokinet Biopharm 13:121-142.
23. Takeda M, Babu E, Narikawa S, Endou H. 2002. Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol 438:137-142.
24. Fujita T, Brown C, Carlson EJ, Taylor T, de la Cruz M, Johns SJ, Stryke D, Kawamoto M, Fujita K, Castro R, Chen CW, Lin ET, Brett CM, Burchard EG, Ferrin TE, Huang CC, Leabman MK, Giacomini KM. 2005. Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). Pharmacogenet Genomics 15:201-209.
25. Cropp CD, Komori T, Shima JE, Urban TJ, Yee SW, More SS, Giacomini KM. 2008. Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol 73:1151-1158.
26. Shima JE, Komori T, Taylor TR, Stryke D, Kawamoto M, Johns SJ, Carlson EJ, Ferrin TE, Giacomini KM. 2010. Genetic variants of human organic anion transporter 4 demonstrate altered transport of endogenous substrates. Am J Physiol Renal Physiol 299:F767-775.
27. Chen Y, Li S, Brown C, Cheatham S, Castron RA, Leabman MK, Urban TJ, Chen L, Yee SW, Choi JH, Huang Y, Brett CM, Burchard EG, Giacomini KM. 2009. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 19:497-504.
28. Shu Y, Brown C, Castron RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM, Giacomini KM. 2008. Effect of genetic variation in the organic cation transporter 1:OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 83, 273-280.
29. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM. 2007. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117:1422-1431.
30. Tahara H, Yee SW, Urban TJ, Hesselson S, Castro RA, Kawamoto M, Stryke D, Johns SJ, Ferrin TE, Kwok PY, Giacomini KM. 2009. Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5). J Pharmacol Exp Ther 329:262-271.
31. Urban TJ, Brown C, Castron RA, Shah N, Mercer R, Huang Y, Brett CM, Burchard EG, Giacomini KM. 2008. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther 83:416-421.
32. Seguin P, Verdier MC, Chanavaz C, Engrand C, Laviolle B, Donnio PY, Malledant Y. 2009. Plasma and peritoneal concentration following continuous infusion of cefotaxime in patients with secondary peritonitis. J Antimicrob Chemother 63:564-567.
33. Sanofi-Aventis Canada Inc. 2010. Product monograph: Claforan(R) sterile cefotaxime sodium, 500 mg, 1 g, 2 g.
34. Verhagen CA, Mattie H, Van Strijen E. 1994. The renal clearance of cefuroxime and ceftazidime and the effect of probenecid on their tubular excretion. Br J Clin Pharmacol 37:193-197.
35. Brown GR. 1993. Cephalosporin-probenecid drug interactions. Clin Pharmacokinet 24:289-300.
36. Guerrini VH, Filippich LJ, English PB, Cao GR, Bourne DW. 1985. Effect of probenecid on the pharmacokinetics of cefotaxime in sheep. J Vet Pharmacol Ther 8:38-46.
37. Savic RM, Kjellsson MC, Karlsson MO. 2009. Evaluation of the nonparametric estimation method in NONMEM VI. Eur J Pharm Sci 37:27-35.
38. Urien S, Laurent N, Barre J, Druguet M, Bouvier D'yvoire M, Maire P. 2004. Pharmacokinetic modelling of cefotaxime and desacetylcefotaxime-A population study in 25 elderly patients. Eur J Clin Pharmacol 60:11-16.
39. Kemmerich B, Lode H, Belmega G, Jendroschek T, Borner K, Koeppe P. 1983. Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam. Antimicrob Agents Chemother 23:429-434.